Fire Needling Plus Filiform Needling for Chronic Migraine With Comorbid Tension-Type Headache
Clinical Research on Fire Needling Combined With Filiform Needling for Chronic Migraine With Comorbid Tension-type Headache
The investigators conducted a multicenter, prospective, randomized controlled clinical study to learn whether fire needling combined with filiform needling applied to pericranial muscle tenderness areas can effectively treat chronic migraine with comorbid tension-type headache. The study will also evaluate the safety and long-term efficacy of this therapy. Its main target questions include:
- Can fire needling significantly reduce the number of headache days per month?
- What is the effect of this therapy on headache intensity, emotional symptoms, and quality of life? The investigators will compare "fire needling at pericranial tender points plus conventional filiform needling" versus "conventional filiform needling alone" to verify whether the key technique of fire needling plus conventional filiform needling provides unique additive value.
Participants will:
- Receive treatment twice per week for 8 weeks (either in the experimental group or the control group)，attend a follow-up visit at week 24 after enrollment
- Keep a headache diary (recording headache frequency, pain intensity, duration, associated symptoms, etc.)
- Regularly complete assessments of emotional status, quality of life, and number of pericranial tender points
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Based on international research progress and our preliminary findings, our team proposes that headache episodes in chronic migraine often present with clinical features of tension-type headache. Patients commonly exhibit widespread pericranial muscle tenderness. Integrating the trigemino-cervical complex (TCC) pathway theory and the long-term foundation of acupuncture treatment for tension-type headache, the investigators propose that chronic migraine primarily develops from the comorbidity of migraine and tension-type headache, with pericranial muscle tenderness being a key pathogenic factor and therapeutic target. Fire-needle pinpointing of tender points in pericranial muscles is a key technique for achieving favorable outcomes.
This multicenter randomized controlled trial will enroll 88 patients with chronic migraine comorbid with tension-type headache. They will be randomly allocated in a 1:1 ratio to either the experimental group or the control group via a central randomization system. The experimental group will receive "fire-needle pinpointing of pericranial tender points plus conventional filiform needle acupuncture," while the control group will receive "conventional filiform needle acupuncture" only. Treatment will be administered twice weekly for 8 weeks, with a follow-up period of 24 weeks.
The study will evaluate clinical efficacy and safety by comparing the two groups in terms of headache days, pain intensity, duration, associated symptoms, emotional status, quality of life, number of pericranial tender points, and safety indicators before and after treatment and at the end of the follow-up period. The aim is to confirm that "pericranial muscle tender areas are the key therapeutic target for chronic migraine comorbid with tension-type headache" and that "fire-needle pinpointing is the key technique for this target." The primary outcome will be the internationally recognized headache frequency. Secondary outcomes will include headache intensity, headache-related emotional symptoms, and health-related quality of life. Long-term follow-up will assess sustained effects, with the goal of providing an acupuncture-based treatment strategy to significantly improve the clinical efficacy for chronic migraine.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Jingwen Dong
- Número de telefone: +8613241104543
- E-mail: a13241104543@163.com
Estude backup de contato
- Nome: Hui Lin Liu
- Número de telefone: +8613681395789
- E-mail: liuhuilin@bjzhongyi.com
Locais de estudo
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100070
- Beijing Tiantan Hospital, Capital Medical University
-
Contato:
- baokai Wang
- Número de telefone: 86+010+59976611
- E-mail: wbk04@126.com
-
Investigador principal:
- baokai Wang
-
Beijing, Beijing Municipality, China, 100010
- Beijing Hospital of Traditional Chinese Medicine
-
Contato:
- Dong Jingwen Dong
- Número de telefone: +8613241104543
- E-mail: a13241104543@163.com
-
Contato:
- Hui Lin Liu
- Número de telefone: 13681395789
- E-mail: liuhuilin@bjzhongyi.com
-
Investigador principal:
- Hui Lin Liu
-
Beijing, Beijing Municipality, China, 100730
- Capital Medical University Affiliated Beijing Tongren Hospital
-
Contato:
- luquan Chen
- Número de telefone: 86+13611373920
- E-mail: chenluquan@ccmu.edu
-
Contato:
- luquan Chen
-
Investigador principal:
- luquan Chen
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Meets the diagnostic criteria for tension-type headaches with pericranial tenderness;
- Meets the diagnostic criteria for chronic migraine;
- 18 years ≤ age ≤ 65 years;
- Has sufficient understanding to complete the necessary examinations and tests for the study;
- Voluntarily joins this study and signs the informed consent form.
Exclusion Criteria:
- Patients complicated with cluster headache or other primary headaches;
- Patients with secondary headaches caused by intracranial space-occupying lesions, cranial infections, etc.;
- Patients complicated with severe heart, liver or kidney impairment, coagulation disorders, infections, severe immunocompromise, or allergic predisposition;
- Patients with alcohol or drug dependence;
- Patients who are unable to cooperate with acupuncture treatment;
- Women who are planning pregnancy, pregnant or breastfeeding;
- Patients who have received acupuncture treatment within 3 months prior to enrollment.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: filiform needling
This point selection protocol follows the international standard acupuncture preventive treatment regimen specified in the Acupuncture Clinical Practice Guideline: Migraine (WFAS 007.8-2023) issued by the World Federation of Acupuncture-Moxibustion Societies (WFAS). Main Points Baihui (GV20), Shenting (GV24), Fengchi (GB20, bilateral), Benshen (GB13, bilateral), Shuaigu (GB8, bilateral), Taiyang (EX-HN5, bilateral). Adjuvant Points For Shaoyang headache: add Toulinqi (GB15), Yangbai (GB14), Fubai (GB10), Zulinqi (GB41), Waiguan (TE5), Yanglingquan (GB34). For Yangming headache: add Touwei (ST8), Hegu (LI4), Neiting (ST44). For Taiyang headache: add Kunlun (BL60), Houxi (SI3). For Jueyin headache: add Taichong (LR3), Qiuxu (GB40). Procedure Fengchi (GB20) is needled 0.5-1 cun toward the nasal tip. All other points are needled perpendicularly. Following the arrival of de qi, even reinforcing-reducing method is applied, with needles retained for 30 minutes. |
Selection of acupoints for filiform needle therapy is integrated with the international standard acupuncture preventive treatment protocol for migraine specified in Acupuncture Clinical Practice Guidelines for Migraine issued by the World Federation of Acupuncture-Moxibustion Societies （WFAS 007.8-2023）.Treatment was administered twice weekly for 8 weeks. Main Acupoints: Baihui (GV20), Shenting (GV24), Fengchi (GB20, bilateral), Benshen (GB13, bilateral), Shuaigu (GB8, bilateral), Taiyang (EX-HN5, bilateral). Adjunct Acupoints: For shaoyang headache: add Toulinqi (GB15), Yangbai (GB14), Fubai (GB10), Zulinqi (GB41), Waiguan (SJ5), Yanglingquan (GB34); For yangming headache: add Touwei (ST8), Hegu (LI4), Neiting (ST44); For taiyang headache: add Kunlun (BL60), Houxi (SI3); For jueyin headache: add Taichong (LR3), Qiuxu (GB40). |
|
Experimental: fire needling combined with filiform needling
Fire needle prickling was applied to the pericranial tenderness areas, combined with filiform needle acupuncture at meridian points.
The acupoint prescription for filiform needle acupuncture was identical to that in the control group.
|
Fire needling was used to puncture pericranial muscle tenderness areas (including the external occipital protuberance, superior nuchal line, nuchal plane, mastoid process; cervicoscapular areas; epicranial aponeurosis - frontal and temporal regions; upper trapezius, sternocleidomastoid, levator scapulae, temporalis, masseter, and occipitofrontalis muscles) in addition to filiform needling at meridian acupoints (same acupoints as the filiform needling group).
Treatment was administered twice weekly for 8 weeks.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Treatment efficacy
Prazo: At week 8 of treatment, and follow-up at week 24 of enrollment
|
Based on the statistics from the headache diaries completed by patients, it is defined as the proportion of subjects who achieve a reduction in headache days of ≥50% after treatment compared to before treatment.
|
At week 8 of treatment, and follow-up at week 24 of enrollment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Headache days
Prazo: Baseline, at week 8 of treatment, and follow-up at week 24 of enrollment.
|
Baseline, at week 8 of treatment, and follow-up at week 24 of enrollment.
|
|
|
Headache Duration
Prazo: Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
|
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
|
|
|
Headache severity
Prazo: Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
|
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
|
|
|
The proportion of monthly headache attacks occurring ≤1 time per month
Prazo: Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
|
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
|
|
|
Migraine-Specific Quality of Life Questionnaire(MSQ) (Version 2.1)
Prazo: Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
|
This is a 14-item questionnaire that measures how migraines affect a patient's daily life and is a highly reliable and valid instrument.
The raw scores are transformed to a 0-100 scale and higher scores reflect greater quality of life.
|
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
|
|
Hamilton Depression Rating Scale, 24-item (HAMD-24)
Prazo: Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
|
The HAMD-24 is a clinician-administered scale used to assess the severity of depressive symptoms.
It consists of 24 items, most of which are scored from 0 to 4 (0 = absent, 4 = very severe), and a few items are scored from 0 to 2 (0 = absent, 2 = marked).
The total score ranges from 0 to 76, with higher scores indicating more severe depression.
|
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
|
|
Hamilton Anxiety Rating Scale, 14-item
Prazo: Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
|
The HAMA-14 is a clinician-administered scale used to assess the severity of anxiety symptoms.
It consists of 14 items, each scored on a 5-point scale from 0 (not present) to 4 (very severe).
The total score ranges from 0 to 56, with higher scores indicating more severe anxiety.
|
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
|
|
The number of tender areas in pericranial muscles and their distribution
Prazo: Baseline, at week 8 of treatment
|
By palpation
|
Baseline, at week 8 of treatment
|
|
Pericranial muscle tender area tenderness threshold
Prazo: Baseline, at week 8 of treatment
|
The subject is instructed to relax naturally and sit on a chair with a backrest.
The researcher uses an electronic pressure meter (SHSCYQ ZMF-50) to perform standardized assessment and recording of the tender points identified through palpation.
A 1 cm² circular probe of the device is placed perpendicularly over the palpated tender point and pressed evenly into the skin at a rate of 0.5 N/s.
The subject presses a feedback button as soon as pain is felt, and the pressure value displayed at that moment is recorded.
Each tender point is measured three times, with an interval of 10 to 15 seconds between measurements.
The average of the three values is calculated as the pressure pain threshold for that tender point.
|
Baseline, at week 8 of treatment
|
|
The status of painkiller intake among subjects
Prazo: Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
|
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
|
|
|
Recording of adverse events
Prazo: During the 8-week treatment period
|
Document adverse events such as needle syncope, hematoma, etc. during acupuncture, along with their grading and management measures.
|
During the 8-week treatment period
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Liu Hui Lin Liu, Beijing Hospital of Traditional Chinese Medicine
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2026BL02-023-01
- 2026-2-2233 (Número de outro subsídio/financiamento: Capital's Funds for Health Improvement and Research)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .